Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
480
datasets available to search
ShareScore release 0.7.1
Dataset results
480 results for “Hormone Receptors”
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
ClinicalTrials.gov study NCT05950945. IPD Sharing: YES. Countries: 10. Publications: 1.
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
ClinicalTrials.gov study NCT02448771. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00082810. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
ClinicalTrials.gov study NCT00553410. IPD Sharing: Not stated. Countries: 20. Publications: 2.
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
ClinicalTrials.gov study NCT03659136. IPD Sharing: NO. Countries: 11. Publications: 2.
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
ClinicalTrials.gov study NCT01870505. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
ClinicalTrials.gov study NCT02040857. IPD Sharing: NO. Countries: 1. Publications: 1.
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
ClinicalTrials.gov study NCT01441947. IPD Sharing: NO. Countries: 1. Publications: 1.
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
ClinicalTrials.gov study NCT00293540. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
ClinicalTrials.gov study NCT01942135. IPD Sharing: YES. Countries: 17. Publications: 23.
Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
ClinicalTrials.gov study NCT00201851. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Prior parental experience attenuates hormonal stress responses and alters hippocampal glucocorticoid receptors in biparental rock doves
Open the record for dataset details and reuse information.
Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population
Open the record for dataset details and reuse information.
Data from: Thyroid hormone receptor beta mutations alter photoreceptor development and function in Danio rerio (zebrafish)
<p>We investigate mutations in <i>trβ2</i>, a splice variant of <i>thrb</i>, identifying changes in function, structure, and behavior in larval and adult zebrafish retinas. Two N-terminus CRISPR mutants were identified. The first is a <i>6BP+1</i> insertion deletion frameshift resulting in a truncated protein. The second is a <i>3BP </i>in frame deletion with intact binding domains. ERG recordings of isolated cone signals showed that the <i>6BP+1</i> mutants did not respond to red wavelengths of light while the <i>3BP </i>mutants did respond. <i>6BP+1 </i>mutants lacked optomotor and optokinetic responses to red/black and green/black contrasts. Both larval and adult <i>6BP+1</i> mutants exhibit a loss of red-cone contribution to the ERG and an increase in UV-cone contribution. Transgenic reporters show loss of cone <i>trβ2</i> activation in the <i>6BP+1 </i>mutant but increase in the density of cones with active blue, green, and UV opsin genes. Antibody reactivity for red-cone LWS1 and LWS2 opsin was absent in the <i>6BP+1</i> mutant, as was reactivity for arrestin3a. Our results confirm a critical role for <i>trβ2</i> in long-wavelength cone development.</p>
Half-Dose Fulvestrant plus Anastrozole as a First-Line Treatment for Hormone Receptor-Positive Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Abstract Objective The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC[HR+]). The objective of this study was to evaluate the cost-effectiveness of F&A in the first-line treatment for PMW-MBC(HR+) in China. Design We constructed a Markov model over a life-time horizon. The clinical outcomes and utility data were obtained from published literature. Cost data were obtained from official Chinese websites. Sensitivity analyses were performed to test result uncertainty. Setting Chinese health care system perspective. Population A hypothetical cohort of adult patients presenting with PMW-MBC(HR+). Interventions F&A compared with full-dose FUL and ANA monotherapy. Main outcome measures The main outcome of this study was the incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY). Results ANA was estimated to have the lowest cost and minimum life years (LYs). The ICER of F&A versus ANA was $15,665.891/QALY with incremental cost and QALY of $12,401.120 and 0.792, respectively, which was less than the willingness-to-pay (WTP) of $29,383/QALY. Compared with F&A, FUL yielded a higher cost and a shorter lifetime; hence, it was identified as a dominated strategy. The univariate sensitivity analysis indicated the price of FUL was the most influential factor in our study. The probability that F&A was cost-effective at a threshold of $29,383/QALY in China was 86.5%. Conclusion F&A is a cost-effective alternative to FUL and ANA monotherapy for the first-line treatment of PMW-MBC(HR+) in China. F&A is a promising first-line treatment for PMW-MBC(HR+), and more research is needed to evaluate the economy of using F&A in other countries.
Data from quantitative real-time PCR of corticotropin-releasing hormone and glucocorticoid receptor in the hippocampus and hypothalamus of rats subjected to midline fluid percussion injury or control sham surgery.
<p>These files contain all data from quantitative real-time PCR of corticotropin-releasing hormone (CRH) and glucocorticoid receptor (GR) measured in the hippocampus and hypothalamus of male and female rats. Rats were randomly assigned to a treatment group before the initiation of the study. Rats received a control sham surgery or were subjected to midline fluid percussion injury to induce a diffuse traumatic brain injury. Tissue biopsies were collected at 7 days post-injury and analyzed via quantitative real-time PCR. </p> <p> </p>
Data from: Stress hormone receptors change as range expansion progresses in house sparrows
As ranges expand, individuals encounter different environments at the periphery than at the centre of the range. Previously, we have shown that glucocorticoids (GCs) vary with range expansion: individuals at the range edge release more GCs in response to restraint. Here, we measured hippocampal mRNA expression of GC receptors (mineralocorticoid, MR and glucocorticoid, GR) in eight house sparrow (Passer domesticus) populations varying in age. We found that individuals closest to the range edge had the lowest expression of MR relative to GR; in all likelihood, this relationship was driven by a marginal reduction of MR mRNA at the range edge. Reduced MR (relative to GR) might allow enhanced GC binding to GR, the lower affinity receptor that would enhance a rapid physiological and behavioural response to stressors. The insights gained from this study are not only enlightening to introduced species, but may also predict how certain species will react as their ranges shift owing to anthropogenic changes.
Tracking conformational transitions of the gonadotropin hormone receptors in a bilayer of (SDPC) poly-unsaturated lipids from all-atom molecular dynamics simulations.
<p>In the present study, we describe the results from a computational microscopy perspective (also known as molecular dynamics simulation) at the atomistic resolution for the two gonadotropin hormone receptors, the follicle-stimulant hormone receptor and the luteinizing/chorionic gonadotropin hormone receptor, which are essential for reproduction in humans.</p>
Dataset for Identification of small-molecule antagonists targeting the Growth Hormone Releasing Hormone Receptor (GHRHR)
<p><span>Active compound dockings, MD systems’ starting conformations, conformations after 1000ns, topology files and parameter files.</span></p>
''Eight-year efficacy update of the HOBOE randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either Tamoxifen or Letrozole or Zoledronic acid + Letrozole'' - dataset
<p>Dataset for analysis of the manuscript ''Eight-year efficacy update of the HOBOE randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either Tamoxifen or Letrozole or Zoledronic acid + Letrozole''</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.